With diagnostic tests gaining increased prominence due to their role in both precision medicine and the COVID-19 pandemic, it’s important to stay on top of new regulatory considerations—and advancements in next generation sequencing that will fuel biomarker-driven research and development.
Precision has launched a new biospecimen collection center, providing clinical- and research-grade leukopaks—mobilized or non-mobilized from healthy and diseased donors, including oncology donors. Invaluable for researchers, these can provide up to 100x more cells from the same donor than PBMCs, bolstering studies that require assay-to-assay consistency.
In this one-hour webinar, a panel of experts—including Precision for Medicine’s Karen Richards—discuss issues from compliance to communications to crafting pre-submission meetings.
Precision for Medicine has partnered with Trialbee, a patient matching and enrollment platform, to extend trial recruitment to a more diverse, targeted patient community—specifically locating those who could be a match for trials in oncology, rare and orphan diseases, and cell and gene therapies.
Given a candle, a box of thumbtacks, and some matches, can you affix a candle to the wall and light it so that it doesn’t drip on the floor? Known as Duncker’s Candle Problem, this puzzle is actually a cognitive performance test, measuring the influence of functional fixedness—the cognitive bias that makes it difficult to use familiar objects in unfamiliar ways.
This discussion will address the operational challenges in the cell and gene therapy space pertaining to supply chain operations and site activation.
You will hear from two leading investigators on the lessons learned, current trends, and insights relevant to the Multiple Myeloma (MM) US and EU research community.